ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1363

Validation of the Self-Administered Comorbidity Questionnaire in Patients with Ankylosing Spondylitis

Carmen Stolwijk1, A.M. Van Tubergen2, Sofia Ramiro3, Ivette Essers1, Marc Blaauw1, Désirée van der Heijde4, Robert B. M. Landewé5, Filip Van den Bosch6, Maxime Dougados7 and Annelies Boonen8, 1Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 2Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, 3Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, 4Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 6Rheumatology, Ghent University Hospital, Ghent, Belgium, 7Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 8Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), comorbidity and questionnaires

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose: Comorbidities can importantly influence the results of clinical studies on functional outcomes as they may act as confounders or effect modifiers. The generic self-administered comorbidity questionnaire (SCQ) is a frequently used instrument to assess common comorbidities which might impact functioning but has never been validated for use in ankylosing spondylitis (AS). Objective was to measure the agreement between SCQ-responses and medical records diagnosis, and to assess construct- and concurrent validity of the SCQ in patients with AS. 

Methods: The SCQ (range 0-45) asks about the presence, treatment and functional limitations of 12 common comorbidities and three additional non-specified medical problems. The SCQ, demographics and indices of disease activity (Bath AS Disease Activity Index [BASDAI]; AS Disease Activity Score- C-reactive protein); physical function (Bath AS Functional Index) and health-related quality of life (HR-QoL; Short form-36 [SF-36], Ankylosing Spondylitis Quality of Life [ASQoL], EuroQoL-VAS), were administered to 98 patients with AS who were followed in the Outcome in Ankylosing Spondylitis International Study (OASIS). The agreement between the SCQ-items and comorbidities retrieved from medical records was calculated by two independent extractors. Concurrent validity was assessed by the correlation with two other comorbidity indices: the Charlson index, a record-based comorbidity index which predicts mortality, and the Michaud/Wolfe index, which predicts functional outcomes. Construct validity was assessed by testing the hypothesis that a valid comorbidity index should correlate with age, function and overall HRQoL. An adapted version of the SCQ (adapted SCQ) was created and validated after removing items on rheumatic diseases (osteoarthritis, back pain, chronic rheumatic disease) because they were conceptually overlapping with the index disease. 

Results: The median SCQ-score was 5 (range 0-19) and the median adapted-SCQ-score was 2 (range 0-13). Frequently reported non-rheumatic comorbidities were hypertension (27.6%), inflammatory bowel disease (10.2%) and depression (9.2%). Agreement between self-report and medical records was moderate to perfect for all diseases included in the SCQ (kappa 0.47-1.00), except for stomach disease, depression, and osteoarthritis (kappa 0.14-0.15). The correlations of the SCQ with the Michaud/Wolfe index and the Charlson index were 0.39 and 0.24 respectively, and of the adapted-SCQ with both indices 0.53 and 0.36 respectively. The SCQ correlated weakly with age (r=0.24) and disease activity (BASDAI r=0.27), and moderately with function (r=0.43) and HRQoL (SF-36 physical r=-0.45; AsQoL r=0.43). The adapted SCQ correlated weakly with age (r=0.28), and moderately with function (r=0.41) and HRQoL (SF-36 physical r=-0.41, ASQoL r=0.32), but not with measures of disease activity.

Conclusion: The SCQ can be used to measure comorbidities which have impact on functional outcomes in AS, but the rheumatic items showed low agreement. Exclusion of these items improved construct and concurrent validity.


Disclosure:

C. Stolwijk,
None;

A. M. Van Tubergen,
None;

S. Ramiro,
None;

I. Essers,
None;

M. Blaauw,
None;

D. van der Heijde,
None;

R. B. M. Landewé,
None;

F. Van den Bosch,
None;

M. Dougados,
None;

A. Boonen,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-the-self-administered-comorbidity-questionnaire-in-patients-with-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology